Table 3.
Economic analysis comparing the cost‐effectiveness of alternative second‐line regimens
| Base case analysis: switch to RT at 5 years post initiation second‐line (~7.5%) | Scenario analysis: switch to RT at baseline HbA1c | |||||
|---|---|---|---|---|---|---|
| Metformin + SU | Metformin + TZD | Metformin + DPP‐4 inhibitor | Metformin + SU | Metformin + TZD | Metformin + DPP‐4 inhibitor | |
| Absolute results | ||||||
| Total costs, £ | 22 960 | 22 788 | 24 057 | 20 975 | 22 013 | 23 105 |
| Total QALYs | 5.58 | 5.55 | 5.64 | 5.53 | 5.56 | 5.63 |
| Total life‐years | 8.35 | 8.25 | 8.33 | 8.34 | 8.27 | 8.34 |
| Incremental results (versus metformin + DPP‐4 inhibitor) | ||||||
| Costs, £ | 1097 | 1269 | 2131 | 1092 | ||
| QALYs | 0.06 | 0.08 | 0.10 | 0.07 | ||
| Life years | −0.02 | 0.07 | −0.01 | 0.06 | ||
| Cost‐effectiveness | ||||||
| Cost/QALY, £ | 18 680 | 15 343 | 20 587 | 15 947 | ||
| Probability CE (%) at: £20k, £30k | 51, 57 | 57, 62 | 49, 61 | 53, 59 | ||
Abbreviations: CE, cost‐effective; k, thousand; RT, rescue therapy.